Pfizer and Merck & Co have filed their diabetes drug ertugliflozin in the US and EU, and the companies hope their alliance will make an impact in the crowded diabetes drug market. The drug is an ...

Merck & Co. managed to increase revenues by ... Sales of its biggest earner, diabetes franchise Januvia/Janumet also declined 3% to $5.89 billion because of growing price pressure and newer ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

as well as its diabetes franchise. However, this decline, in my opinion, is not critical for Merck's financial position, since sales of Januvia and Janumet account for only 3.1% of its total revenue.

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Merck is recognized for its extensive product portfolio covering treatments in areas like oncology, diabetes, cardiovascular diseases, vaccines, and infectious diseases. The company also operates ...